Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Lung cancer, Non small cell lung cancer (NSCLC), Secondary cancers
Closed
Phase 3
This trial is comparing a new drug called MK-3475A with pembrolizumab for non small cell lung cancer (NSCLC).
It is for people:
who are having their first treatment for NSCLC that has spread to another part of the body
with a large number of cancer cells that have a called PD-L1
Recruitment start: 21 February 2025
Recruitment end: 3 November 2025
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Toby Talbot
Merck Sharp & Dohme Ltd
Last reviewed: 10 Nov 2025
CRUK internal database number: 20010
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
